Each IBS DR represents one ordinary share and trades on the Regulated Market of the Frankfurt Stock Exchange (FSE) under the symbol IBSG.
Formerly, IBS depositary receipts were included for trading in the Open Market of the FSE.
The IBS GDRs and equity shares have not been registered under the US Securities Act of 1933 and may not be offered or sold in the US, absent registration or an applicable exemption from the registration requirements.
BNY Mellon Depositary Receipts business CEO Michael Cole-Fontayn said BNY Mellon believes IBS’ decision to be the first to list depositary receipts on the FSE’s Regulated Market is well-timed and will bring the company enhanced exposure.
“Their decision also further demonstrates the significant role depositary receipts are playing in the global marketplace,” Cole-Fontayn said.
IBS is an information technology and consulting services company based in Russia, incorporated in Isle of Man, with business operations in Russia, the CIS, Europe, the US, Canada and Vietnam.
